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Review question 
What is the association of thyroid function with the risk of fibrosis of the liver, heart and lung in humans? 
 
Searches 
An expert medical librarian will perform the search through Pubmed, Web-of-Science, Embase Ovid and Medline Ovid. There will be no 
language nor date restrictions. 
 
Types of study to be included 
 Inclusion criteria 
 (i) Observational studies that investigated the association of thyroid function with fibrosis of the liver, heart, or lung, in humans;  
(ii) Studies reporting effect estimates with 95% confidence intervals (CIs), or mean differences with standard deviations (p-values), or prevalence 
differences (p-values).  
(iii) No restrictions on publication year or language.  
 
Exclusion criteria 
(i) Case-reports, letters to the editor, proceedings, reviews, systematic reviews, meta-analyses, conference abstracts, and animal studies.  
(ii) Studies that focused exclusively on the role of thyroid function altering medications on fibrotic diseases.  
 
Condition or domain being studied 
Thyroid function, fibrosis. 
 
Participants/population 
Population with data available on thyroid function and fibrotic diseases of the liver, lung, and heart. 
 
Intervention(s), exposure(s) 
Thyroid hormones, thyroid status 
Main outcome(s) 
Fibrotic diseases of the liver, heart and lung, evaluated via noninvasive or invasive measures. 
 
Data extraction (selection and coding) 
This systematic review will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
guidelines for transparent reporting. Four electronic databases, including Pubmed Publisher, Web-of-Science, Embase and Medline Ovid, will be 
searched with the help of expert librarians. Two independent reviewers will screen the titles and abstracts. The full text articles of potentially 
relevant articles will be obtained and independently evaluated. Any disagreement regarding inclusion will be resolved through consensus. A third 
independent reviewer will be assigned in case of persisting disagreement. Full texts and reference lists of the selected articles will be hand searched 
in order to identify additional studies. A predesigned data collection form will be used to extract relevant information from the selected studies, 
including article source, sample size, demographics of study participants, methods of assessing thyroid function and fibrosis, study results and 
conclusions.  
 
Risk of bias (quality) assessment 
The quality of the included studies will be assessed separately by two reviewers using the Newcastle–Ottawa Scale (NOS) for non-randomized 
studies in meta-analyses. The NOS scale evaluates the study quality based on 3 domains, namely selection of participants, comparability of study 
groups, and ascertainment of the outcomes of interest. Each study could have a maximum of 9 stars.  
 
Strategy for data synthesis 
We will provide a narrrative synthesis of the findings of eligible studies. The effect estimates with 95% confidence intervals (CIs), or mean 
differences with standard deviations (p-values), or prevalence differences (p-values), will be reported in a summary table. If a meta-analysis is 
possible, the effect estimates will be pooled, and forest plots will be constructed. Heterogeneity will be assessed by using the I2 statistic, with I2 
≤25% considered as low, I2 between 25% and 75% as moderate, and I2 ≥75% as high. Statistical analyses will be performed in Stata version 15.1 
(StataCorp LLC, Texas, USA).   
 
Analysis of subgroups or subsets 
The following sensitivity analyses will be performed, if applicable: (1) We will use random-effects models in order to test for heterogeneity; (2) 
We will exclude the studies that provide unadjusted estimates 
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